Roche: to present new data at conference in July
(CercleFinance.com) - Roche announced on Monday that new data from its hemophilia A clinical program will be presented at the 2020 Congress of the International Society of Thrombosis and Hemostasis.
The congress will be held next month, from 12 to 14 July.
"Data will include updated safety results from the phase IIIb STASEY study of Hemlibra® (emicizumab) and new results from the phase III HAVEN 5 study of Hemlibra. Data will also include insights into the impact of living with haemophilia A. Spark Therapeutics (a member of the Roche Group) will also present data from the initial dose cohorts of its phase I/II SPK-8011 gene therapy study," the group said.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
The congress will be held next month, from 12 to 14 July.
"Data will include updated safety results from the phase IIIb STASEY study of Hemlibra® (emicizumab) and new results from the phase III HAVEN 5 study of Hemlibra. Data will also include insights into the impact of living with haemophilia A. Spark Therapeutics (a member of the Roche Group) will also present data from the initial dose cohorts of its phase I/II SPK-8011 gene therapy study," the group said.
Copyright (c) 2020 CercleFinance.com. All rights reserved.